公开(公告)号：EP1083168A1

公开(公告)日：2001-03-14

申请号：EP99921247.5

申请日：1999-05-25

申请人： TAISHO PHARMACEUTICAL CO., LTD ,  Sato, Fumie

发明人： SATO, Fumie ,  TANAMI, Tohru ,  KAMEO, Kazuya ,  YAMADA, Kenji ,  OKUYAMA, Shigeru ,  ONO, Naoya

IPC分类号： C07C405/00 ,  A61K31/557

CPC分类号： A61K31/5575 ,  A61K31/557 ,  C07C405/00 ,  Y10S514/923

摘要： A prostaglandin derivative represented by formula (I) wherein X represents a halogen atom, n is an integer of 1 to 5, R 1 represents a C 3-10 cycloalkyl group, a C 3-10 cycloalkyl group substituted with a C 1-4 alkyl group, a C 4-13 cycloalkylalkyl group, a C 5-10 alkyl group, a C 5-10 alkenyl group, a C 5-10 alkynyl group or a bridged cyclic hydrocarbon group, R 2 represents a hydrogen atom, a C 1-10 alkyl group or a C 3-10 cycloalkyl, or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP1083168B1

公开(公告)日：2003-10-22

申请号：EP99921247.5

申请日：1999-05-25

申请人： TAISHO PHARMACEUTICAL CO., LTD ,  Sato, Fumie

发明人： SATO, Fumie ,  TANAMI, Tohru ,  KAMEO, Kazuya ,  YAMADA, Kenji ,  OKUYAMA, Shigeru ,  ONO, Naoya

IPC分类号： C07C405/00 ,  A61K31/557

CPC分类号： A61K31/5575 ,  A61K31/557 ,  C07C405/00 ,  Y10S514/923

摘要： A prostaglandin derivative represented by formula (I) wherein X represents a halogen atom, n is an integer of 1 to 5, R represents a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with a C1-4 alkyl group, a C4-13 cycloalkylalkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, R represents a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl, or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP1330240A2

公开(公告)日：2003-07-30

申请号：EP01968558.5

申请日：2001-09-06

申请人： MCW Research Foundation ,  Taisho Pharmaceutical Co. Ltd.

发明人： ROMAN, Richard, J. ,  HARDER, David, R. ,  MIYATA, Noriyuki ,  SATO, Masakazu ,  KAMEO, Kazuya ,  OKUYAMA, Shigeru

IPC分类号： A61K31/00 ,  A61K31/155 ,  A61K31/145 ,  A61K31/20 ,  A61K31/4192 ,  A61K31/4174 ,  A61K39/395 ,  A61K48/00 ,  A61P9/10 ,  A61P31/00 ,  A61P25/00 ,  A61P25/06 ,  A61P25/28

CPC分类号： A61K31/15 ,  A61K31/20 ,  A61K31/4164 ,  A61K31/4192 ,  A61K48/00

摘要： A method for treating cerebral vascular diseases in a human or non-human animal is disclosed. The method involves inhibiting 20-HETE synthesizing enzyme activity sufficiently to increase or prevent a decrease in cerebral blood flow in the human or non-human animal. This can be obtained by treating the animal with inhibitors of CYP4A or CYP4F family of enzymes, such as HET0016, 17-ODYA (17-octadecynoic acid), DDMS (dibromododecenyl methylsulfimide), 1-ABT (1-aminobenzotriazole) and miconazole, or with an antibody to 20-HETE synthetizing enzyme or with an antisense oligo-nucleotide directed against 5' end of CYP4A1, CYP4A2, CYP4A11, CYP4F2 or CYP4F3.

公开(公告)号：EP0597095B1

公开(公告)日：1996-10-30

申请号：EP92908246.9

申请日：1992-04-21

申请人： TAISHO PHARMACEUTICAL CO. LTD

发明人： SATO, Fumie ,  AMANO, Takehiro ,  KAMEO, Kazuya ,  TANAMI, Tohru ,  MUTOH, Masaru ,  ONO, Naoya ,  GOTO, Jun

IPC分类号： C07C405/00

CPC分类号： C07C405/00

摘要： Object: to provide a novel prostaglandin E1 which is excellent in drug efficacy while reduced in adverse reactions as compared with conventional ones. Constitution: a PGE1 analogue represented by general formula (I) and its salt, wherein A represents vinylene or ethynylene; R1 represents hydrogen, C¿1? to C6 alkyl or aryl; and R?2¿ represents C¿5? to C10 branched aliphatic hydrocarbyl.

公开(公告)号：EP0597095A1

公开(公告)日：1994-05-18

申请号：EP92908246.9

申请日：1992-04-21

申请人： TAISHO PHARMACEUTICAL CO. LTD

发明人： SATO, Fumie ,  AMANO, Takehiro ,  KAMEO, Kazuya ,  TANAMI, Tohru ,  MUTOH, Masaru ,  ONO, Naoya ,  GOTO, Jun

IPC分类号： C07C405/00

CPC分类号： C07C405/00

摘要： Object: to provide a novel prostaglandin E₁ which is excellent in drug efficacy while reduced in adverse reactions as compared with conventional ones. Constitution: a PGE₁ analogue represented by general formula (I) and its salt, wherein A represents vinylene or ethynylene; R¹ represents hydrogen, C₁ to C₆ alkyl or aryl; and R² represents C₅ to C₁₀ branched aliphatic hydrocarbyl.

摘要翻译： 目的：提供新型前列腺素E 1，与传统药物相比，药物疗效优异，副反应减少。 构成：由通式（I）表示的PGE 1类似物及其盐，其中A代表亚乙烯基或亚乙炔基; R 1代表氢，C 1至C 6烷基或芳基; R 2代表C 5至C 10支链脂族烃基。

公开(公告)号：EP0591532A1

公开(公告)日：1994-04-13

申请号：EP92908341.8

申请日：1992-04-21

申请人： TAISHO PHARMACEUTICAL CO. LTD

发明人： SATO, Fumie ,  AMANO, Takehiro ,  KAMEO, Kazuya ,  TANAMI, Tohru ,  MUTOH, Masaru ,  ONO, Naoya ,  GOTO, Jun

IPC分类号： C07C405/00

CPC分类号： C07C405/00

摘要： Object: to provide a novel prostaglandin E₁ which is excellent in drug efficacy and prolonged action while reduced in adverse reactions as compared with conventional ones. Constitution: a PGE₁ analogue represented by general formula (I) and its salt, wherein R¹ represents hydrogen, C₁ to C₆ alkyl or aryl; and R² represents C₃ to C₆ alkyl or C₃ to C₆ alkenyl.

摘要翻译： 目的：提供一种新颖的前列腺素E 1，其与常规药物相比在药物疗效和延长作用方面优异，并且在不良反应中减少。 组成：由通式（Ⅰ）代表的PGE 1类似物及其盐，其中R 1代表氢，C 1至C 6烷基或芳基; R 2代表C 3至C 6烷基或C 3至C 6链烯基。